Factory 99% Capecitabine Powder CAS 154361-50-9 Chemical Intermediate Capecitabine

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A997
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Capecitabine
• CAS: 154361-50-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Capecitabine
Appearance	White Powder
CAS NO.	154361-50-9
Storage	Keep in a cool, dry, dark location

 

Capecitabine is an oral fluoropyrimidine carbamate and prodrug designed to selectively target tumor tissues. It is metabolized in the body through a three-step enzymatic cascade into 5-fluorouracil (5-FU), a potent thymidylate synthase inhibitor. This mechanism disrupts DNA synthesis in rapidly dividing cancer cells, making it effective against various solid tumors.

 

1. Advanced or Metastatic Breast Cancer: Approved for HER2-negative or anthracycline/taxane-resistant cases, often combined with docetaxel.
2. Colorectal Cancer: Used as adjuvant therapy for stage III colon cancer, neoadjuvant/adjuvant treatment for locally advanced rectal cancer, and first/second-line therapy for metastatic disease (e.g., in combination with oxaliplatin).
3. Gastric Cancer: Employed in adjuvant or palliative settings, particularly in combination regimens.

1. Targeted Antitumor Activity: Converts to 5-FU preferentially in tumor tissues via high thymidine phosphorylase (TP) expression, enhancing efficacy while minimizing systemic toxicity.
2. Chemotherapeutic Synergy: Enhances response rates when combined with other agents (e.g., platinum salts, taxanes) by exploiting drug-induced TP upregulation in tumors.
3. Oral Convenience: Simplifies administration compared to intravenous 5-FU, improving patient compliance and reducing hospitalization needs.